| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA706: Ozanimod for treating relapsing–remitting multiple sclerosis |
|
Medicine details |
|
| Medicine name | ozanimod (Zeposia®) |
| Formulation | 0.23 mg, 0.46 mg & 0.92 mg capsules |
| Reference number | 2490 |
| Indication | Treatment of adults with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features |
| Company | Celgene Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 23/05/2020 |
| NICE guidance | TA706: Ozanimod for treating relapsing–remitting multiple sclerosis |